Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates
Stoke Therapeutics reported Q3 2026 revenue of $11.3 million and a net loss of $73.6 million ($1.08 per share), with R&D spending up sharply to $59.8 million as the Phase 3 EMPEROR study advances. Pipeline news dominated: all 162 patients are enrolled in the Phase 3 EMPEROR study of zorevunersen in Dravet syndrome, ~110 have completed the Week 28 primary-endpoint visit, and a data readout is expected in Q3 2027 with an NDA submission planned for H2 2027 following a successful FDA alignment meeting. The second program, STK-002 for ADOA, is progressing through Phase 1 OSPREY dose escalation, with initial safety and efficacy data anticipated in H1 2027.
Key figures
- Revenue
- 11255000
- Guidance
- Phase 3 EMPEROR data readout Q3 2027; NDA submission planned H2 2027; STK-002 OSPREY initial safety/efficacy data H1 2027; cash funds operations into early 2028
- Revenue Yoy
- 6%
- Q3 net loss
- 73600000
- Ytd revenue
- 26808000
- Ytd net loss
- 185265000
- Q3 sga expense
- 28739000
- Q3 r and d expense
- 59831000
- Patients through week 28
- ~110
- Patients through week 52
- ~20
- Emperor enrolled patients
- 162
- Cash and marketable securities
- 358800000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.